The potential oncology treatment, Xtandi (enzalutamide) and leuprolide, was tested among about 1,000 patients with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
The study compared Xtandi and leuprolide, Xtandi alone and a placebo plus leuprolide, and the research’s primary endpoint was metastasis-free survival. The Xtandi monotherapy reduced the risk of metastasis or death by 37 percent.
For the secondary endpoint, prostate-specific antigen progression, Xtandi plus leuprolide and Xtandi monotherapy reduced the risk, respectively, by 93 percent and 67 percent.
The two companies said they will use the data “to support a potential regulatory submission for Xtandi in this indication in 2023.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
